Time filter

Source Type

London and, United Kingdom

Jackson C.,University of Otago | Sirohi B.,Max Cancer Center | Cunningham D.,Lymphoma Unit | Horwich A.,Institute of Cancer Research and Royal Marsden NHS Foundation Trust | And 2 more authors.
Annals of Oncology

Background: Lymphocyte-predominant Hodgkin disease (LPHD) is a rare subtype of Hodgkin lymphoma, for which there is limited evidence regarding the presentation, natural history and treatment outcomes. Patients and methods: We conducted a single-institution retrospective review all of patients diagnosed with LPHD over a 30-year period. Results: Eighty-eight patients were included. Median follow-up was 13 years. Local radiotherapy or chemoradiotherapy resulted in durable disease control in patients with stage I or II disease. Advanced stage at presentation, presence of B symptoms, low albumin, and either partial response or stable disease to first treatment were associated with worse treatment outcomes. Relapse rate for the entire cohort was 44%, with an 8% rate of transformation to large-cell lymphoma. Rituximab in combination with chemotherapy resulted in durable remission in a heavily pretreated subgroup. Outcomes with autologous transplant are discussed. Conclusion: Our series has the longest follow-up of any report, includes the only series of patients treated with autologous transplant, and has the largest group of patients treated with rituximab and chemotherapy in this indication. © The Author 2010. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. Source

Hodgson D.C.,University of Toronto | Mikhaeel N.G.,Lymphoma Unit
Current Oncology Reports

Radiation therapy (RT) has been described as the most effective single agent in the treatment of lymphoma; however, contemporary lymphoma treatment rarely relies on single agents. In the modern era, the selection of appropriate patients for combined modality therapy has become increasingly complex over the last decade with the transition to immunochemotherapy, the emergence of functional imaging for response evaluation, and the improvement in conformal avoidance of normal tissues when delivering RT. Recent evidence demonstrates that selected patients with DLBCL have significantly better outcomes when RT is added to immunochemotherapy; however, there are important knowledge gaps regarding the use of functional imaging to facilitate treatment selection. This article will review the current evidence regarding the optimal use of combined modality therapy for DLBCL. © 2015, Springer Science+Business Media New York. Source

Meignan M.,Lymphoma Unit | Gallamini A.,Az. Ospedaliera S. Croce e Carle | Itti E.,Lymphoma Unit | Barrington S.,Kings College London | And 2 more authors.
Leukemia and Lymphoma

One hundred and ninety-three hemato-oncologists and nuclear medicine specialists from 23 countries joined the 2-day Third International Workshop on Interim Positon Emission Tomography in Lymphoma held in September 2011. Forty scientific posters were presented or discussed in the plenary session. Final results of international validation studies of Deauville criteria and change in maximum standardized uptake value (ΔSUVMAX) analysis in Hodgkin lymphoma (HL) as well as non-Hodgkin lymphoma (NHL) were reported. These studies were confirmatory of the prognostic value of interim positron emission tomography (PET) in 261 patients with advanced HL after two cycles of ABVD (adriamycin, bleomycin, vinblastine, dacarbazine) when reported with the 5-point scale and in 120 patients with diffuse large B-cell lymphoma (DLBCL) after two cycles of a rituximab-containing immunochemotherapy regimen when using ΔSUV analysis. A preliminary consensus on interim PET was established among experts on the assessment of marrow response, refinement of scores 4 and 5 of the 5-point scale, the need to focus on interim PET results for NHL other than DLBCL, methods to compute ΔSUV and factors affecting ΔSUV measurements. Recommendations were given on how to use ΔSUV analysis in NHL taking into account the levels of initial SUVMAX and interim SUVMAX. For the next meeting (October 2012), the majority of the audience strongly favored extending the topics, including in the workshop all aspects of PET in lymphoma, rather than just limiting it to interim PET. © 2012 Informa UK, Ltd. Source

Corns R.,Kings College | Crocker M.,Kings College | Kumar A.,Kings College | Salisbury J.,Kings College | And 3 more authors.
Acta Neurochirurgica

Low-grade primary T-cell lymphoma of the central nervous system is extremely rare. We present a case developing in a previously fit young woman presenting with symptoms of raised intracranial pressure and found on CT to have a cerebellar mass. Biopsy of this lesion revealed features of non-Hodgkin's lymphoma with histochemical analysis confirming T-cell phenotype and a Ki67 proliferation index of only 1%. Contrary to the prevailing view in the literature, the patient's clinical condition deteriorated following high-dose intravenous methotrexate and improved after a short course of whole-brain radiotherapy. © Springer-Verlag 2009. Source

Meignan M.,Lymphoma Unit | Gallamini A.,BMT Unit | Haioun C.,Lymphoma Unit | Polliack A.,Hebrew University of Jerusalem
Leukemia and Lymphoma

One hundred and fifty hemato-oncologists and nuclear medicine specialists from more than 20 countries joined in April 2010 the 2-day Second International Workshop on interim PET in lymphoma. During the nuclear medicine session the advantages of the five-point scale Deauville criteria for interim PET reporting over the other sets of visual criteria were presented. The specific problems of PET reporting in escalationde-escalation trials in Hodgkin lymphoma HL were addressed as well as the limitations of visual analysis for early PET evaluation in non-Hodgkin lymphoma NHL. The applicability, efficacy, and reproducibility of quantitative criteria ΔSUV max analysis and tumorliver SUV ratio for interim PET in NHL were reported. In retrospective and prospective series. Some of the interim PET-based clinical trials ongoing worldwide in HL and NHL were reported. In early-stage HL, three trials aimed at determining the feasibility of omitting radiotherapy in interim PET negative patients, and in advanced-stage HL two PET-based ABVD escalation or BEACOPP de-escalation trials, in NHL two studies reported preliminary results of interim PET in follicular lymphoma, in DLBCL a round-table discussion pointed out the lack of definite criteria for interim PET, and a few observational studies in DLBCL reported the comparison of the various techniques of interim PET reporting visual versus quantitative. The preliminary results of two international validation studies of the five-point scale criteria in HL and NHL launched in 2009 were reported. The presentations of the meeting are available on http://eitti.free.fr © 2010 Informa UK, Ltd. Source

Discover hidden collaborations